Trial Profile
Nivolumab and Ibrutinib for Relapsed or Refractory Central Nervous System Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Nivolumab (Primary)
- Indications B-cell lymphoma; CNS cancer; Lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 16 Apr 2024 Planned End Date changed from 15 Jun 2024 to 30 Jun 2025.
- 16 Apr 2024 Planned primary completion date changed from 15 Jun 2024 to 30 Jun 2025.
- 12 Dec 2023 According to Results presented at the 65th American Society of Hematology Annual Meeting and Exposition, The trial planned to enroll 20 patients in both cohort A and B, but closed early due to slow accrual, due in part to the COVID19 pandemic.